Colorectal cancer (CRC) is one of the most common cancers worldwide, and the identification of new biomarkers for CRC is valuable for its diagnosis and treatment. We aimed to screen differentially expressed glycoproteins (especially O-glycoproteins) and to identify diagnostic or therapeutic candidates for colorectal cancer (CRC) based on different Tn antigen expression levels. Fresh cancer tissues and adjacent healthy tissues were obtained from CRC patients and classified into three groups based on their Tn antigen expression: CRC with negative Tn expression (CRC Tn -), CRC with positive Tn expression (CRC Tn + ) and normal control without Tn expression (NC). Protein extractions were separated and identified by iTRAQ technology. Glycoproteins and O-glycoproteins were selected using UniProt and DAVID. Deep bioinformatic analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KO), was used to annotate this O-glycoprotein interaction network. Subsequently, two O-glycoproteins were verified by western blotting and immunohistochemistry in either LS174T cells or CRC tissues. We found that 330 differentially expressed proteins were identified by iTRAQ between CRC Tnand NC tissues, 317 between CRC Tn + and NC tissues, and 316 between CRC Tnand Tn + tissues. Of the 316 proteins, 55 glycoproteins and 19 O-glycoproteins were identified and analyzed via deep informatics. Namely, different Tn antigen expression levels in CRC led to differential protein expression patterns, especially for glycoproteins and O-glycoproteins. Decorin and SORBS1, two representative functional O-glycoproteins, were significantly downregulated in the CRC Tn + tissues compared with the level in the CRC Tnor NC tissues. Based on this deep bioinformatic analysis, Decorin and SORBS1 are hypothesized to be involved in the TGF-β and PPAR-γ signaling pathways, respectively.
Introduction
Colorectal carcinoma (CRC) is one of the most common cancers worldwide. However, the early diagnosis rate of CRC is low, and surgery is less effective in patients with more advanced CRC (stage Ⅲ), for whom the mortality rate is high and the prognosis is poor. Early diagnosis depends on a combination of early screening of non-specific biomarkers such as CEA and CA199 and pathological endoscopic biopsies (1, 2) . Consequently, most patients are diagnosed at the intermediate or late stages and deprived of the opportunity for surgery. Therefore, the lack of specific biomarkers for earlier diagnosis and therapeutic targets leads to high CRC mortality worldwide (2) (3) (4) , and CRC is one of the primary causes of cancer-related death in the world. Intervention in the early stage could cure colorectal cancer, and the identification of CRC biomarkers may be a convenient way to achieve this objective.
Recent studies show that the pathogenesis of cancer is highly related to glycosylation (5, 6) . The increased expression of N-acetylgalactosamine (GalNAc) on the surface of cancer cells is one of the characteristics of the altered glycosylation pathway (7) . Mucins are highly O-glycosylated proteins that play pivotal roles in cell adhesion, inflammation, cell proliferation, apoptosis and tumorigenesis (8) (9) (10) (11) . The mucin-associated carbohydrate Tn antigen is composed of a GalNAc residue covalently O-linked to a serine/threonine (12, 13) , which is shielded in healthy tissues and benign tumors but occurs in ~90% of all human primary carcinomas (14) . The synthesis of sialyl-Tn antigen (sTn) is regulated by the sialyltransferase ST6GalNAc, which competes against O-glycan elongating glycosyltransferases and prevents tumors from exhibiting longer O-glycans (12, 15) . Abnormal Tn antigen expression has been observed in lung, breast, ovarian and CRC (16) (17) (18) (19) (20) . Tn antigen is also associated with malignancy and represents a potential marker of malignant transformation (17, 21, 22) . Recent studies have shown that higher Tn antigen expression is observed in CRC patients (14, 23, 24) . Tn antigen may promote cancer metastasis by secretion of transforming growth factor-β (TGF-β) in the tumor microenvironment (25) . In addition, Tn was found to be expressed in moderately differentiated tumors but not in poorly differentiated carcinomas (26) , and a deficiency of core-1-derived O-glycans could delay the onset and progression of breast cancer (18) . Furthermore, Tn antigen is related to poor prognosis in patients with breast cancer (27) . Above all, we hypothesized that the Tn antigen plays a central role in the early diagnosis and the development of CRC. However, the Tn-related proteins participating in its pathogenic progression remain unclear. It is therefore worthwhile to analyze the expression of Tn-related proteins. In the present study, we used iTRAQ to screen differentially expressed proteins between Tn-positive and Tn-negative CRC tissues and to identify accessible proteins as useful diagnostic biomarkers or new therapeutic candidates for CRC.
Materials and methods
Patient information and sample preparation. A series of primary colon resections were prospectively collected between November 2011 and March 2012 from the Department of Minimally Invasive Surgery of the Second Xiangya Hospital in Changsha. Each resection contained both colon tumor samples and adjacent healthy tissues, and lymph nodes were also collected. Some of the samples were kept at -80˚C until analysis, and the remaining samples were fixed in 4% paraformaldehyde and sent to the Pathology Department for further analysis. CRC samples were screened for Tn staining via immunochemical examination by Dr Lijun Xia from the Oklahoma Medical Research Foundation (OMRF; Oklahoma City, OK, USA). Based on the Tn antigen expression, the samples were divided into three groups as follows: CRC with negative Tn expression (CRC Tn -), CRC with positive Tn expression (CRC Tn + ) and normal control without Tn expression (NC). No patient was treated with any kind of chemotherapy. The patient information is shown in Table Ⅰ .
This study was approved by the Institutional Ethics Committee of the Second Xiangya Hospital of Central South University. All participants provided written informed consent.
Protein extraction and iTRAQ labeling. One gram of fresh tissues was ground in liquid nitrogen and suspended in 5 ml of lysis buffer with supplements (7 mM urea, 2 mM sulfourea, 0.1% PMSF, 65 mM DTT) on ice for 30 min, followed by centrifugation for 15 min at 24,1488 x g. The supernatant was collected, and the protein concentration was determined using the Bradford Protein Assay kit (Bio-Rad, USA).
For peptide labeling, a peptide mixture from each group was labeled with iTRAQ tags according to the kit's protocol (Applied Biosystems, Foster City, CA, USA). Protein samples from adjacent healthy tissues were labeled with reagent 114. Tn -CRC and Tn + CRC samples were labeled with reagent 117 and 118, respectively.
2D LC-MS/MS. The peptide mixture was reconstituted and acidified with buffer A (10 mM KH 2 PO 4 , pH 2.6, and 25% acetonitrile) (ACN; Thermo Fisher Scientific, Inc., Fair Lawn, Nj, USA) and loaded onto a strong cation exchange (SCX) chromatography column (The Nest Group, Inc. , Southborough, MA, USA) on a 20AD high-performance liquid chromatography (HPLC) system (Shimadzu, Kyoto, japan). The peptides were eluted at a flow rate of 200 µl/min with a gradient of 0-80% buffer B for 60 min. The elution was monitored by absorbance at 214/280 nm, and fractions were collected every minute. The collected fractions were combined and desalted on a C18 cartridge (Waters Corp., Milford, MA, USA).
All samples were resuspended in 50 µl HPLC buffer A (5% ACN and 0.1% formic acid), loaded in the ZORBAX 300SB-C18 reverse-phase column (5 µm, 300 Å, 0.1x150 mm; Michrom BioResources, Auburn, CA, USA). The peptides were separated for >90 min using a linear gradient of 5-35% HPLC buffer B (95% ACN and 0.1% formic acid) at a flow rate of 300 nl/min. The MS analysis was performed using a QSTAR XL analyzer (Applied Biosystems) coupled with a 20AD HPLC system (Shimadzu). Precursor ions were selected across the mass range of 400-1,800 m/z. Four precursors were selected for MS/MS analyses across the mass range of 100-2,000 m/z. Data analysis and bioinformatics. Protein identification and relative iTRAQ quantification were performed with the Paragon algorithm in the ProteinPilot Software 3.0 (revision 114732; Applied Biosystems). The results were further processed using the Pro Group algorithm (Applied Biosystems), where isoform-specific quantification was adopted to trace the differences between the expression levels of various isoforms. Quantitative ratios of reporter ions, calculated by comparing the peak areas of each of these reporter ions in the mass spectrum, were used to evaluate the expression change of the protein in different samples. Normalization was performed during the quantification to correct the experimental bias. To accept proteins as showing differential expression between different groups, we strictly followed the following criteria. It was mandatory for proteins to be identified with >95% confidence, and the protein confidence threshold cutoff was 1.3 (unused ProtScore). Proteins with significant P-values (P<0.05) were considered differentially expressed. The false discovery rate (FDR) for protein detection was calculated as FDR = (2 x reverse)/(forward + reverse). UniProt was used to annotate the proteins in the biological process and molecular function categories in the human UniProtKB/Swiss-prot database (version 3.52, November 2008).
Gene Ontology and pathway analysis. Gene Ontology (GO) was used to annotate the proteins by biological process and molecular function. We translated the genes into putative amino acid sequences and aligned these genes against a set of protein sequences from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Each protein was assigned to KEGG orthology (KO), and differentially enriched KO pathways were identified.
Cell culture and immunofluorescence staining of the Tn antigen. LS174T cells (a gift from Dr Lijun Xia, OMRF), were For immunofluorescence staining of the Tn antigen, LS174T cells on cover slips were fixed in 4% paraformaldehyde (Sigma), permeabilized with 0.1% Triton X-100 (Promega) at room temperature for 15 min, and blocked with 1% BSA (Gibco) for 30 min at room temperature. The slides were incubated with a mouse monoclonal antibody against Tn (made by OMRF) at 1:50 overnight at 4˚C, followed by a 1-h incubation at room temperature with the secondary antibody (anti-mouse antibody, 1:2,000; jackson ImmunoResearch, West Grove, PA, USA). The sections were counterstained with DAPI for 2 min and then visualized and photographed under a confocal laser scanning microscope (LaVision BioTec GmbH, Bielefeld, Germany). To confirm the expression of Decorin or SORBS1, 3x10 6 LS174T cells were harvested, and the total proteins were prepared for subsequent western blotting.
Western blotting. The extracted proteins from tissues or cells were resolved by SDS-PAGE gradient gel (5% spacer gel and 8% separation gel). After electrophoresis, samples were transferred to a polyvinylidene fluoride membrane, blocked at room temperature for 1 h with 5% milk, and incubated with a mouse antibody against Decorin (1:500; Abcam, USA), a rabbit antibody against SORBS1 (1:1,000; Abgent, USA) or a mouse antibody against β-actin (1:1,000; Abcam) at 4˚C overnight. The membranes were washed with buffer three times, incubated with an HRP-conjugated anti-rabbit secondary antibody (1:5,000) or anti-mouse secondary antibody (1:20,000) (both from Abcam) at room temperature for 1 h, and visualized with an ECL kit (GE Healthcare). Specific signals were quantified from exposed X-ray film using a scanner with BandScan 4.30 densitometry software and are expressed as integrated intensity units relative to the β-actin signals.
Immunohistochemistry assay in tissues. To detect the immunohistochemical expression of Decorin or SORBS1, the embedded tissues were cut into 5-µm thin sections. These sections were incubated with an antibody against Decorin (1:50) or SORBS1 at 1:100 overnight at 4˚C after blocking with 2% BSA. Subsequently, the sections were treated with an HRP-conjugated anti-rabbit (1:5,000) or anti-mouse secondary antibody (1:20,000) at room temperature for 1 h. The DAB Detection kit (EliVision Super DAB; Maixin-Bio, Fuzhou China) for blocking non-specific binding and antibody detection was used. The sections were then counterstained with hematoxylin. The immunostaining results were detected under a light microscope.
Statistics. All observations were confirmed by at least three independent experiments. Image-Pro Plus 6.0 was used to analyze the results from IHC, and Quantity One v4.6.2 was used for western blotting. For quantitative data, t-test and ANOVA were used for statistical analysis. The analyses were performed using SPSS Statistics 20 (SPSS Inc. Chicago, IL, USA). P<0.05 was considered statistically significant.
Results
Tn antigen expression and clinicopathological factors in CRC patients. Sixteen patients with a confirmed diagnosis of CRC were included. The enrolled patients included three males and three females, with ages ranging from 50 to 81 years (mean age, 62). Most were diagnosed with moderately differentiated cancer. The Tn antigen expression was detected in 3 patients, as shown in Table Ⅰ .
Identification of Decroin and SORBS1 as differentially expressed glycoproteins in CRC by iTRAQ. A total of 1,051 non-redundant proteins in the genome (UniProt) were significantly identified from the number of MS/MS spectra and number of peptides using a 2% false discovery rate (FDR) as the cutoff in the triplicate independent experiments. Of these, 750 had quantitative information, and more than two peptides were matched to these proteins. There were 330 differentially expressed proteins between CRC Tnand NC tissues, 317 between CRC Tn + and NC tissues, and 316 between CRC Tnand CRC Tn + tissues. Among the 316 proteins, there were 55 glycoproteins and 19 O-glycoproteins. Twelve of the 19 O-glycoproteins were also differentially expressed between the CRC Tn -/CRC Tn + tissues and normal mucosal tissues (Tables Ⅱ and Ⅲ ). Sixty-five proteins were differentially expressed in CRC Tntissue compared with NC, while 74 proteins were significantly altered in CRC Tn + compared with NC. Forty proteins displayed differential expression between CRC Tnand CRC Tn + , and 25 of these proteins were simultaneously significantly differentially expressed in CRC Tnand Tn + tissues compared with NC ( Fig. 1) .
Among the significantly differentially expressed proteins, there were a few glycosylated proteins, especially O-glycosylated proteins. Fifty-five glycosylated proteins exhibited differential expression between CRC Tn + and CRC Table Ⅲ . Differentially expressed glycosylated proteins in Tn + compared with Tntissues Differential expression Pt.
Peptides (Tables Ⅱ and Ⅲ ).
Differential expression of Decorin and SORBS1 in CRC tissues or cell lines with different expression levels of the Tn antigen.
We investigated whether the expression of Decorin and SORBS1 is related to the Tn antigen expression level in CRC tissues. The relative quantification of Decorin using iTRAQ showed that Decorin was more highly expressed in normal tissues than in CRC tissues, especially Tn + tissues ( Fig. 2A) , as in the results for SORBS1 using iTRAQ. To verify the function of Decorin and SORBS1 in carcinogenesis, we used western blotting and IHC to quantify their expression in NC, CRC Tnand CRC Tn + tissues. As shown in Fig. 2B -E, Decorin expression was significantly decreased in the CRC Tn + tissues compared with the CRC Tnand NC tissues (P<0.05). A significant difference was also found in the expression of SORBS1 among Tn + , Tnand NC tissues, as shown in Fig. 3 .
To verify the Tn antigen expression levels in Tn + cells, we demonstrated that Tn antigen was significantly increased in Tn + cells compared with Tncells via immunofluorescence assay (Fig. 4A) . We also detected the expression levels of Decorin and SORBS1 in the LS174T cells with different Tn expression levels and found that the expression of Decorin was significantly decreased in the Tn + LS174T cells compared with that noted in the Tncells (P<0.05) ( Fig. 4B and C) . Surprisingly, SORBS1 was not detected in the LS174T cells.
Functional analysis of 12 differentially expressed O-glycosylated proteins related to CRC. Functional analysis of the
O-glycosylated proteins showed that the proteins participated in metabolic processes, in the regulation of biological processes, in the formation of membrane proteins of cells and organelles, and in the binding to other proteins (Table Ⅳ ). In the present study, we paid particular attention to the analysis of metabolic processes, especially for SORBS1 and Decorin. SORBS1 was correlated with cell-cell adhesion via paxillin (PXN), the PPAR signaling pathway and the insulin signaling pathway via INS/IRS1. It could also interact with the Cbl proto-oncogene (CBL). Decorin participated in the TGF-β pathway via TGFB1/3 and connected with jUN, neurocan (NCAN), syndecan (SDC) and FOS-like protein-1 (FOSL1), as shown in the network in Fig. 5 and Table Ⅴ .
Correlation of Decorin and SORBS1 expression in CRC with clinicopathological factors.
To ascertain whether the expression of Decorin and SORBS1 was related to neoplasm staging, we compared the expression of Decorin and SORBS1 with TNM stages. Decorin and SORBS1 were not significantly increased in TNM stage 0-Ⅱ compared with stage Ⅲ (Table Ⅵ, P>0.05). However, a significant correlation was found between the expression of the two proteins and the tumor differentiation stages. Decorin and SORBS1 were significantly increased in moderately differentiated tissues compared with poorly differentiated tissues (Table Ⅵ, P<0.05).
Discussion
Since the Tn antigen participates in the development of CRC (24, 28, 29) , we investigated specific Tn antigen-related biomarkers as novel indicators for diagnostic or therapeutic targets. We analyzed the differentially expressed proteins between CRC Tn + and CRC Tntissues with the iTRAQ-based proteome technique. In the present study, 25 proteins were significantly expressed only in the CRC groups compared with the NC tissues, indicating that these proteins may participate in the development of CRC. The expression of 10 proteins was differently regulated in CRC Tntissues compared with CRC Tn + tissues but not in NC tissues. Considering that the Tn antigen was expressed mainly in moderately differentiated and not poorly differentiated tumors, we investigated the potential effects of these 10 proteins on the evaluation of the prognosis of carcinoma. Thirteen proteins were significantly differentially regulated among three groups, demonstrating the potential role of these 13 proteins in the initiation and progression of CRC.
Given that the Tn antigen is related to the disarrangement of O-glycosylation, we chose 12 differentially expressed O-glycosylated proteins for further study. Among these O-glycoproteins, Keratin 8, Keratin 18, Decorin, Sorbin, SORBS1 and CD44 antigen were reported to correlate with the initiation and progression of CRC. As yet, few studies have investigated the relationship between SORBS1, Decorin, the Tn antigen and the development of CRC (30, 31) . SORBS1 belongs to a growing family of proteins containing a Sorbin homology (SoHo) domain and three SH3 domains in the C-terminal region. It plays an important role in adhesion between cells and the matrix via the SH3 domain (32, 33) . A study showed that c-Abl kinase, the product of the c-abl proto-oncogene, mediated the effects of cell adhesion on cell cycle progression or gene expression (34) . Another study found that c-Abl could bind the SH3 domain of SORBS1 (30) . Considering the abnormal adhesion between cancer cells, we hypothesized that SORBS1 may play a role in preventing CRC metastasis. Furthermore, SORBS1 together with vinculin was found to inhibit cell migration (35) . p53 promoted the expression of SORBS1 in EB-1 cells (36, 37) . As SORBS1 is dependent on p53, mutations which correlate with cancer metastasis via the downregulation of adhesion proteins, we deduced that SORBS1 reduction may participate in the development and progression of carcinoma. In the present study, we found that SORBS1 expression was significantly downregulated in the CRC Tn + tissues compared with levels in the CRC Tnand the healthy tissues, especially in poorly differentiated tissues. From the GO network, it was observed that SORBS1 also is connected with the proto-oncogene Cbl (38) . According to the functional analysis, SORBS1 participates in the PPAR-γ pathway, which has been identified as a 'driver gene' in CRC initiation and progression (39) . Thus, we demonstrated that downregulation of SORBS1 plays a potential role in the development of CRC via the PPAR-γ pathway (Fig. 6) .
Moreover, Decorin controls the expression of p21, affects the activation of EGFR, promotes the apoptosis of cancer cells, and plays a key role in the immune response (40) . Downregulation of Decorin is related to poor prognosis in breast cancer, and a similar role was found in lung cancer and lymphoma (27, (41) (42) (43) . However, highly-expressed Decorin suppressed the development and metastasis of breast cancer (43) . Few studies on the relationship between Decorin and CRC have been established. Bi et al found that the Decorin expression level was significantly reduced which may lead to tumorigenesis in mice (40) . Our results showed that Decorin was decreased in the CRC Tn + tissue compared with this level in the CRC Tnand the control tissues, supporting the aforementioned conclusion. Furthermore, functional analysis revealed that Decorin is involved in the TGF-β pathway, which has been found to be associated with the onset and progression of intestinal cancer (44) (45) (46) . In addition, Decorin is linked with jUN, NCAN, SDC1 and FOSL1. NCAN is involved in the modulation of cell adhesion and migration (47) , and SDC1 functions as an integral membrane protein and participates in cell proliferation, cell migration and cell-matrix interactions via its receptor for extracellular matrix proteins. Altered SDC1 expression has been detected in several different tumor types (48) (49) (50) . The FOS gene family consists of four members: FOS, FOSB, FOSL1, and FOSL2. These genes encode leucine zipper proteins that can Compared with TNM Ⅲ, the expression of the two proteins was not significantly increased (P>0.05); b expression of the two proteins was significantly increased in the moderately differentiated group (P<0.05).
dimerize with proteins of the jUN family, thereby forming the transcription factor complex AP-1 (51) . As such, the FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation (52, 53) . Therefore, we conclude that downregulated Decorin could lead to the development of cancer via the TGF-β pathway as our results confirmed (Fig. 6 ).
To verify our hypothesis that abnormal O-glycosylation may control the development of carcinoma via influencing the expression of SORBS1 and Decorin, we also tested their expression in vitro. The expression of Decorin was in accordance with the results obtained from western blotting. Notably, SORBS1 was not detected in the Tn + colorectal cells. As it is not a secretory protein, it is not possible that it was excreted outside the cell. We speculated that the SORBS1 protein level might be too low to be detected in vitro. Further studies with a larger number of samples are needed to clarify the relationship between Decorin, SORBS1 and neoplasm staging. 
